title: Building an outcome predictor model for diffuse large B-cell lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) patients are treated using relatively homogeneous protocols, irrespective of their biological and clinical variability. Here we have developed a protein-expression-based outcome predictor for DLBCL. Using tissue microarrays (TMAs), we have analyzed the expression of 52 selected molecules in a series of 152 DLBCLs. The study yielded relevant information concerning key biological aspects of this tumor, such as cell-cycle control and apoptosis. A biological predictor was built with a training group of 103 patients, and was validated with a blind set of 49 patients. The predictive model with 8 markers can identify the probability of failure for a given patient with 78% accuracy. After stratifying patients according to the predicted response under the logistic model, 92.3% patients below the 25 percentile were accurately predicted by this biological score as "failure-free" while 96.2% of those above the 75 percentile were correctly predicted as belonging to the "fatal or refractory disease" group. Combining this biological score and the International Prognostic Index (IPI) improves the capacity for predicting failure and survival. This predictor was then validated in the independent group. The protein-expression-based score complements the information obtained from the use of the IPI, allowing patients to be assigned to different risk categories.
authors.affiliation: Universidad de Granada, Spain.
authors.forename: Ana-Isabel
authors.initials: AI
authors.lastname: Sáez
authors.forename: Antonio-José
authors.initials: AJ
authors.lastname: Sáez
authors.forename: María-Jesús
authors.initials: MJ
authors.lastname: Artiga
authors.forename: Alberto
authors.initials: A
authors.lastname: Pérez-Rosado
authors.forename: Francisca-Inmaculada
authors.initials: FI
authors.lastname: Camacho
authors.forename: Ana
authors.initials: A
authors.lastname: Díez
authors.forename: Juan-Fernando
authors.initials: JF
authors.lastname: García
authors.forename: Máximo
authors.initials: M
authors.lastname: Fraga
authors.forename: Ramón
authors.initials: R
authors.lastname: Bosch
authors.forename: Silvia-María
authors.initials: SM
authors.lastname: Rodríguez-Pinilla
authors.forename: Manuela
authors.initials: M
authors.lastname: Mollejo
authors.forename: Cristina
authors.initials: C
authors.lastname: Romero
authors.forename: Lydia
authors.initials: L
authors.lastname: Sánchez-Verde
authors.forename: Marina
authors.initials: M
authors.lastname: Pollán
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000401:mortality*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor